Galderma Secures Triple Approval for Next-Gen Restylane Syringe — Galderma Group AG

Event summary

Galderma's new Restylane syringe received regulatory approval in the EU, U.S., and Canada on February 25, 2026.
The syringe features ergonomic design enhancements, optimized needle connection, and sustainable packaging.
Developed with input from over 70 aesthetics practitioners, it supports multiple facial indications and hand treatments.
Approved for use with Restylane Lyft™ Lidocaine, Restylane Eyelight™, and Restylane-L (Classyc™ Lidocaine in some markets).
The syringe reduces clinic waste by up to 30% through compact, recyclable packaging.

The big picture

This approval solidifies Galderma's leadership in injectable aesthetics, particularly as demand for minimally invasive procedures continues to rise. The ergonomic and sustainability features address key practitioner pain points while aligning with broader industry trends toward precision medicine and environmental responsibility. With over 77 million Restylane treatments administered globally, this innovation could further extend the brand's dominance in the $10B+ dermatology market.

What we're watching

Market Adoption: How quickly practitioners will transition to the new syringe and whether it drives increased Restylane usage.
Competitive Response: Whether competitors like Allergan or Merz will accelerate their own syringe innovations in response.
Sustainability Impact: The pace at which Galderma can expand its sustainable packaging initiatives across other product lines.